FDA biopharmaceutical drug approvals increase despite slower development time
The U.S. Food and Drug Administration has passed nearly twice as many biopharmaceutical drug approvals in the last 10 years than it did in the 1990s, a news release from the Tufts Center for the Study of Drug Development has indicated.

Sutent Gains FDA Approval To Treat Pancreatic Neuroendocrine Tumors
The Pfizer drug Sutent (sunitinib) has been approved for the treatment of advanced pancreatic neuroendocrine tumors by the U.S. Food and Drug Administration (FDA). Sutent is the second targeted drug to be approved this month for the treatment of pancreatic neuroendocrine tumors, which make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less ...

FDA Approves Incivek For Hepatitis C
The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin ...